Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. […]
Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) have been assigned an average rating of “Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among […]